Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Summary by Stemwell Science News
Halda Therapeutics announced that the US FDA granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with mCRPC. [Halda Therapeutics] Press Release
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Stemwell Science NewsStemwell Science News

Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Halda Therapeutics announced that the US FDA granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with mCRPC. [Halda Therapeutics] Press Release

Read Full Article
targetedonc.comtargetedonc.com

HLD-0915 Receives FDA Fast Track Designation for mCRPC Treatment

FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development and potential breakthrough treatment.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Friday, August 15, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

News
For You
SearchBlindspotLocal